Leaflet: information for the user
Ziprasidone hydrochloride 60 mg hard capsules EFG
ziprasidone hydrochloride
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Ziprasidone cinfa capsules is a medication belonging to the group of medications known as antipsychotics.
Ziprasidone is indicated for the treatment of schizophrenia in adults, a mental illness characterized by the appearance of one or more of the following symptoms: hearing, seeing or feeling things that do not exist, believing in something that is not true, having unusual suspicions, being absent and having difficulty establishing social relationships, nervousness, depression or anxiety.
Furthermore, ziprasidone is used in adults and in children and adolescents from 10 to 17 years old for the treatment of symptoms of moderate severity mania in bipolar disorder, a mental illness characterized by alternating phases of euphoric mood states (mania) or depressed states. During the episodes of mania, the most characteristic symptoms are: euphoric behavior, exaggerated self-esteem, increased energy, decreased need for sleep, lack of concentration or hyperactivity and repetition of risky behaviors.
Do not take ziprasidona cinfa
See the section “Taking ziprasidona cinfa with other medicines” later.
Warnings and precautions
Consult your doctor or pharmacist before starting to take ziprasidona cinfa:
Immediately contact your doctor if you experience any of the following symptoms:
Inform your doctor that you are taking ziprasidona cinfa capsules before undergoing any diagnostic tests (including blood tests, urine tests, liver function tests, heart rhythm tests, etc.) as it may alter the results.
Children and adolescents
The safety and efficacy of ziprasidona in the treatment of schizophrenia in children and adolescents have not been established.
Taking ziprasidona cinfa with other medicines
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine.
Do not take Ziprasidona cinfaif you are taking medicines for heart rhythm disturbances or medicines that may affect heart rhythm, such as:
Class IA and III antiarrhythmics, arsenic trioxide, halofantrine, levomethadyl acetate, mesoridazine, thioridazine, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, dolasetron mesylate, mefloquine, sertindole, or cisapride. These medicines may alter heart rhythm by prolonging the QT interval. If you have any additional questions about this effect, consult your doctor.
Consult your doctor or pharmacist before starting to take Ziprasidona cinfa.
Inform your doctor or pharmacist if you are using or have used recently medicines for the treatment of:
See the section “Do not take ziprasidona cinfa” earlier.
Taking ziprasidona cinfa with food, drinks, and alcohol
Ziprasidona cinfa capsules MUST BE TAKEN DURING MAIN MEALS.
Do not consume alcoholic beverages during treatment with ziprasidona cinfa capsules, as this may increase the risk of adverse effects.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor before using this medicine.
Pregnancy:
Do not take ziprasidona cinfa capsules during pregnancy unless your doctor tells you to, as this medicine may harm your baby. Always use a suitable contraceptive method.
The following symptoms may occur in newborn babies of mothers who have taken ziprasidona in the last trimester (last three months of pregnancy): tremors, stiffness, and/or muscle weakness, tendency to sleep, agitation, respiratory problems, and feeding difficulties. If your baby develops any of these symptoms, contact your doctor.
Breastfeeding:
Do not breastfeed your baby while taking ziprasidona cinfa capsules. This is because small amounts may pass into breast milk.
Contraception:
If you can become pregnant, you should use a suitable contraceptive method while taking this medicine.
Driving and operating machinery
Ziprasidona may cause symptoms such as drowsiness, dizziness, or visual disturbances, and may decrease your reaction time. These effects, as well as the underlying disease, may make it difficult for you to drive vehicles or operate machinery. Therefore, do not drive, operate machinery, or engage in other activities that require special attention, until your doctor assesses your response to this medicine.
Ziprasidona cinfa contains sodium.
This medicine contains less than 23 mg of sodium (1 mmol) per capsule; that is, it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The capsules should be swallowed whole, without chewing, and should be taken with food. It is essential not to chew the capsules as this may affect the point at which the medication is absorbed in the intestine.
Ziprasidone hydrochloride capsules should be taken twice a day, one capsule in the morning during a consistent breakfast and one in the evening during dinner (see blister). Make sure to take this medication at the same time every day.
Adults
The recommended dose is 40 to 80 mg of ziprasidone twice a day with food.
In long-term treatments, your doctor may adjust the dose. It is recommended not to exceed the maximum dose of 160 mg per day.
Children and adolescents with bipolar mania
The recommended starting dose for treatment is 20 mg per day in a single dose with food, after which your doctor will indicate your optimal dose. It is recommended not to exceed the maximum dose established by weight range of 160 mg per day in the case of children weighing 45 kg or more and 80 mg per day in children weighing less than 45 kg.
The safety and efficacy of ziprasidone in the treatment of schizophrenia in children and adolescents have not been established.
Individuals over 65 years old
If you are over 65 years old, your doctor will decide on the appropriate dose for you. The dose for individuals over 65 years old is sometimes lower than that used in younger individuals. Your doctor will indicate the appropriate dose for you.
Patients with liver problems
If you have liver problems, you may need to take a lower dose of ziprasidone hydrochloride capsules. Your doctor will indicate the correct dose for you.
If you take more ziprasidone hydrochloride than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service at telephone 91 562 04 20, indicating the medication and the amount ingested.
If you have taken too much ziprasidone hydrochloride, you may experience drowsiness, tremors, convulsions, and involuntary movements of the head and neck.
If you forget to take ziprasidone hydrochloride
It is essential to take ziprasidone hydrochloride at the same time every day. If you forget to take a dose, take it as soon as you remember. However, if it is close to the next dose, skip the missed dose and take the next one at its scheduled time.
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with ziprasidone hydrochloride
Your doctor will indicate for how long you should take ziprasidone hydrochloride. Do not stop taking this medication unless your doctor tells you to.
It is essential to continue treatment, even if you feel better. If you stop treatment too soon, symptoms may return.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
It may often be difficult to distinguish the symptoms of your illness from side effects.
STOP taking ziprasidone cinfa and contact your doctor immediately if you experience any of the following serious side effects:
Frequent side effects (can affect up to 1 in 10 patients):
Rare side effects (can affect up to 1 in 100 patients):
Very rare side effects (can affect up to 1 in 1,000 patients):
You may experience some of the side effects mentioned below. These potential side effects are generally mild to moderate in nature and may disappear over time. However, if the side effect is severe or persistent, contact your doctor.
Very frequent side effects (can affect more than 1 in 10 patients):
Frequent side effects (can affect up to 1 in 10 patients):
Rare side effects (can affect up to 1 in 100 patients):
Very rare side effects (can affect up to 1 in 1,000 patients):
Unknown frequency (cannot be estimated from available data):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Blister packs:
Do not store at a temperature above 30°C.
Bottles:
Do not store at a temperature above 30°C.
Shelf life once the packaging is opened: 6 months
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of ziprasidone cinfa
Appearance of the product and contents of the packaging
Ziprasidone cinfa 60 mg hard capsules are presented in the form of hard gelatin capsules. The capsules are white.
Packaging sizes:
Aluminum/aluminum blisters containing 14, 20, 30, 50, 56, 60, or 100 capsules.
HDPE plastic bottles containing 100 capsules.
Only some packaging sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta.
31620 Huarte (Navarra)-Spain
Responsible manufacturer
PharmaPath S.A
28is October 1,
Agia Varvara, 123 51
Greece
or
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta.
31620 Huarte (Navarra)-Spain
Last review date of this leaflet:May 2020
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
You can access detailed and updated information on this medicine by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/80960/P_80960.html
QR code to:https://cima.aemps.es/cima/dochtml/p/80960/P_80960.html
The average price of Ziprasidona cinfa 60 mg capsulas duras efg in July, 2025 is around 98.49 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.